Abstract Library

#3026 IMP3 and Ki-67-Factors of Poor Clinical Outcome in Neuroendocrine Tumors of the Lung

Introduction: Insulin- like growth factor-II messenger RNA- binding protein- 3 (IMP3) is often detected in malignant neoplasm of different sites. Ki-67 proliferative index, although helpful in diagnosing neuroendocrine tumours of lung, has not been recognised as prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bełz A, Stęplewska K, Głogowska- Szeląg J,

Keywords: carcinoid, IMP3, Ki-67, neuroendocrine,

#3015 Biopsy Specimen Diagnosis in Pulmonary Carcinoids, A Shot in the Dark

Introduction: Pulmonary carcinoids (PCs) are rare well-differentiated neuroendocrine tumors, which can be separated into typical carcinoid (TC) and atypical carcinoid (AC). Advised treatment for local carcinoid disease is surgical resection using lobectomy, while parenchymal saving strategies such as sub-lobar or endobronchial resection might be considered for TC. In general, pre-operative diagnosis using a (transbronchial/transthoracic) biopsy sample is performed to demonstrate malignancy. However, TC and AC classification can solely be performed on surgical resection specimens, which may challenge pre-operative treatment decisions.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Moonen L

Authors: Moonen L, Derks J, Hermans B, Dingemans A, Speel E,

Keywords: pulmonary, neuroendocrine, carcinoid, biopsy, resection, diagnosis,

#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study

Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Faggiano A, Di Maio S, Tafuto S, Mocerino C, Di Sarno A,

Keywords: neuroendocrine tumor, medical therapy, sequence of treatments,

#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,

Keywords: PDR001, immunotherapy, NET,

#1845 Mismatch Repair (MMR) Protein Expression is Uncommon in Poorly Differentiated Neuroendocrine Carcinoma

Introduction: Microsatellite instability (MSI) has been reported to occur in a significant proportion of neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinomas (MANEC) (11 out of 89 cases, Sahnane et al, ERC 2015). It might be predictive of response to immunotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hadoux J

Authors: Hadoux J, Malka D, Berdeloux A, Planchard D, Boige V,

Keywords: Neuroendocrine carcinoma, mismatch repair, microsatellite instability,